A Phase 2 interventional study of Calcifediol Oral Capsule and Placebo oral capsule in Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases and Vitamin D Deficiency, sponsored by OPKO Health, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 503rd largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2018, is one of 156 in phase 2, and was the 551st registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 46 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 699 that completed or were terminated, 345 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
OPKO Health, Inc. has 9 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 (calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism (SHPT) in Subjects with Vitamin D Insufficiency (VDI) and Chronic Kidney Disease Requiring Regular Hemodialysis.
Each subject must meet the following criteria to be enrolled in this study:
Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:
Exhibit during the initial screening visit:
Exhibit after the 8-week washout period (if required due to prior use of etelcalcetide, cinacalcet, calcitriol or other 1α- hydroxylated vitamin D analogs, or vitamin D supplementation):
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from the study:
History (prior 2 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus
≥6.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
Drug: Calcifediol Oral Capsule
Placebo Oral Capsules/weekly for 26 weeks
Drug: Placebo oral capsule
Capsule, weekly
Also known as: CTAP101
Capsule, weekly
Number of Participants With Response During Efficacy Assessment Period
To evaluate the efficacy of repeated dosing with 900 mcg per week of CTAP101 extended release (ER) Capsules versus placebo in raising mean serum total 25-hydroxyvitamin D (25D) to ≥50 ng/mL and in reducing mean plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline.
Time frame: 26 weeks
Total 25-hydroxyvitamin D Response Analysis During Efficacy Period
Summary of participants with mean serum total 25-hydroxyvitamin D ≥50 ng/mL at the end of treatment
Time frame: 26 weeks
Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period
Summary of participants who experienced a reduction in mean plasma iPTH by greater than 30% from the pre-treatment baseline
Time frame: 26 weeks
Pharmacokinetic (PK) Profile (Cmax) of Serum Calcifediol
To assess Cmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Pharmacokinetic (PK) Profile (Tmax) of Serum Calcifediol
To assess Tmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Pharmacokinetic (PK) Profile (AUC0-t) of Serum Calcifediol
To assess AUC0-t of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
Time frame: 0, 4, 8, 12, 16, 20, 24, 30, 36, 42 and 48 hours post-dose (single and repeat dose)
Pharmacodynamic Analysis of 1,25-dihydroxyvitamin D
Effect of CTAP101 on 1,25-dihydroxyvitamin D
Time frame: 26 weeks
| Milestone | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Started | 33 | 11 |
| Completed | 25 | 8 |
| Not completed | 8 | 3 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Subject moving out of state | 1 | 0 |
To evaluate the efficacy of repeated dosing with 900 mcg per week of CTAP101 extended release (ER) Capsules versus placebo in raising mean serum total 25-hydroxyvitamin D (25D) to ≥50 ng/mL and in reducing mean plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline.
| Participants | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Number of Participants With Response During Efficacy Assessment Period | 4 | 0 |
Summary of participants with mean serum total 25-hydroxyvitamin D ≥50 ng/mL at the end of treatment
| Participants | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Total 25-hydroxyvitamin D Response Analysis During Efficacy Period | 28 | 1 |
Summary of participants who experienced a reduction in mean plasma iPTH by greater than 30% from the pre-treatment baseline
| Participants | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Number of Participants With Intact Parathyroid Hormone (iPTH) Response During Efficacy Assessment Period | 4 | 0 |
To assess Cmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
| ng/mL | CTAP101 Capsules 900mcg |
|---|---|
| Cmax (single PK) | 45.5 ± 20.17 |
| Cmax (repeat PK) | 181.0 ± 171.92 |
To assess Tmax of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
| hours | CTAP101 Capsules 900mcg |
|---|---|
| Tmax (single PK) | 0.6 ± 0.41 |
| Tmax (repeat PK) | 2.5 ± 2.72 |
To assess AUC0-t of serum calcifediol after a single dose of 900 mcg at the start of the study (Single Dose PK Period), and a repeat dose of 300 mcg at the end of the study (Repeat Dose PK Period)
| hour x ng/mL | CTAP101 Capsules 900mcg |
|---|---|
| AUC0-t (single PK) | 9118.4 ± 3557.65 |
| AUC0-t (repeat PK) | 95820.7 ± 44858.77 |
Effect of CTAP101 on 1,25-dihydroxyvitamin D
| pg/mL | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Baseline | 9.4 ± 1.2 | 12.6 ± 2.7 |
| Visit 24 | 50.7 ± 7.8 | 13.4 ± 4.1 |
Collected over 26 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTAP101 Capsules 900mcg/Weekly | 0/32 (0%) | 15/32 (46.9%) | 29/32 (90.6%) |
| Placebo Capsules Weekly | 0/11 (0%) | 4/11 (36.4%) | 9/11 (81.8%) |
| Event | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| Corona virus infectionInfections and infestations | 3/32 | 1/11 |
| OsteomyelitisInfections and infestations | 3/32 | 1/11 |
| PneumoniaInfections and infestations | 0/32 | 1/11 |
| Urinary tract infection staphylococcalInfections and infestations | 0/32 | 1/11 |
| Demyelinating polyneuropathyNervous system disorders | 0/32 | 1/11 |
| Atrial fibrillationCardiac disorders | 0/32 | 1/11 |
| BradycardiaCardiac disorders | 0/32 | 1/11 |
| Cardiac arrestCardiac disorders | 0/32 | 1/11 |
| Incision site complicationInjury, poisoning and procedural complications | 0/32 | 1/11 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/32 | 1/11 |
| Event | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly |
|---|---|---|
| HypotensionVascular disorders | 5/32 | 3/11 |
| DiarrhoeaGastrointestinal disorders | 5/32 | 1/11 |
| ConstipationGastrointestinal disorders | 4/32 | 0/11 |
| NauseaGastrointestinal disorders | 4/32 | 0/11 |
| TachycardiaCardiac disorders | 3/32 | 0/11 |
| VomitingGastrointestinal disorders | 3/32 | 0/11 |
| MalaiseGeneral disorders | 3/32 | 0/11 |
| Urinary tract infectionInfections and infestations | 3/32 | 1/11 |
| Accidental overdoseInjury, poisoning and procedural complications | 3/32 | 0/11 |
| Vascular access malfunctionInjury, poisoning and procedural complications | 3/32 | 0/11 |
Modified intention-to-treat (mITT) population.
| Age, Customized(Participants) | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly | Total |
|---|---|---|---|
| < 65 years old | 21 | 7 | 28 |
| >= 65 years old | 7 | 2 | 9 |
| Sex: Female, Male(Participants) | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly | Total |
|---|---|---|---|
| Female | 12 | 5 | 17 |
| Male | 16 | 4 | 20 |
| Ethnicity (NIH/OMB)(Participants) | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 23 | 5 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CTAP101 Capsules 900mcg/Weekly | Placebo Capsules Weekly | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 5 | 25 |
| White | 7 | 4 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jul 2018 to primary completion in Feb 2021, 31 months.
Results were first posted in Mar 2025, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calcifediol
Renal Insufficiency, Chronic →